[
  {
    "ts": null,
    "headline": "Solid Results Boosted Abbott Laboratories’ (ABT) Performance in Q1",
    "summary": "Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Growth & Income Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P 500 Index ended Q1 down 4.3%, marking a turbulent start to 2025. The volatility that began in February was triggered by factors including policy […]",
    "url": "https://finnhub.io/api/news?id=1b00bd4e73460e805d64a240d47096720bcfe663aa87921373ae43983380f8d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747748512,
      "headline": "Solid Results Boosted Abbott Laboratories’ (ABT) Performance in Q1",
      "id": 134609110,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Growth & Income Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P 500 Index ended Q1 down 4.3%, marking a turbulent start to 2025. The volatility that began in February was triggered by factors including policy […]",
      "url": "https://finnhub.io/api/news?id=1b00bd4e73460e805d64a240d47096720bcfe663aa87921373ae43983380f8d0"
    }
  },
  {
    "ts": null,
    "headline": "Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?",
    "summary": "Based on the average brokerage recommendation (ABR), Abbott (ABT) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?",
    "url": "https://finnhub.io/api/news?id=993c070e43a8ac49511a479f8709333863f621fba73156ccf434eb1477094b9c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747747811,
      "headline": "Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?",
      "id": 134628329,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Based on the average brokerage recommendation (ABR), Abbott (ABT) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?",
      "url": "https://finnhub.io/api/news?id=993c070e43a8ac49511a479f8709333863f621fba73156ccf434eb1477094b9c"
    }
  },
  {
    "ts": null,
    "headline": "Janus Henderson Global Life Sciences Diversified ADR Managed Account Q1 2025 Commentary",
    "summary": "The Portfolio returned 1.36% (gross) and the MSCI World Health Care Index SM returned 5.29%.",
    "url": "https://finnhub.io/api/news?id=62b609fa1d5756badcdc2024a29cd0511dca54f3d6b9f9baa7ca9b6096bc8b15",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747732200,
      "headline": "Janus Henderson Global Life Sciences Diversified ADR Managed Account Q1 2025 Commentary",
      "id": 134608635,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1479272648/image_1479272648.jpg?io=getty-c-w1536",
      "related": "ABT",
      "source": "SeekingAlpha",
      "summary": "The Portfolio returned 1.36% (gross) and the MSCI World Health Care Index SM returned 5.29%.",
      "url": "https://finnhub.io/api/news?id=62b609fa1d5756badcdc2024a29cd0511dca54f3d6b9f9baa7ca9b6096bc8b15"
    }
  },
  {
    "ts": null,
    "headline": "Unpacking Q1 Earnings: Baxter (NYSE:BAX) In The Context Of Other Medical Devices & Supplies - Diversified Stocks",
    "summary": "As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - diversified industry, including Baxter (NYSE:BAX) and its peers.",
    "url": "https://finnhub.io/api/news?id=b4f862c35381480ef2c8e13cb48965f15a0b071b692580982923e04508e66d89",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747711999,
      "headline": "Unpacking Q1 Earnings: Baxter (NYSE:BAX) In The Context Of Other Medical Devices & Supplies - Diversified Stocks",
      "id": 134609111,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - diversified industry, including Baxter (NYSE:BAX) and its peers.",
      "url": "https://finnhub.io/api/news?id=b4f862c35381480ef2c8e13cb48965f15a0b071b692580982923e04508e66d89"
    }
  }
]